Literature DB >> 28362521

A nationwide study on parathyroid carcinoma.

Eeva M Ryhänen1, Helena Leijon2, Saara Metso3, Eija Eloranta4, Pirkko Korsoff5, Petteri Ahtiainen6, Päivi Kekäläinen7, Marjo Tamminen8, Raija Ristamäki9, Otto Knutar10, Eliisa Löyttyniemi11, Leo Niskanen1, Mika Väisänen12, Ilkka Heiskanen12, Matti J Välimäki1, Markku Laakso13, Caj Haglund12,14, Johanna Arola2, Camilla Schalin-Jäntti1.   

Abstract

BACKGROUND: Parathyroid carcinoma (PC) is rare and diagnostically challenging. Reported outcomes are rather poor and the incidence might be increasing.
MATERIAL AND METHODS: We performed a nationwide study on all cases (n= 32) diagnosed in 2000-2011 in Finland, and compared clinical and histopathological characteristics and outcome to atypical parathyroid (APA; n= 28) and parathyroid adenomas (PA; n= 72). The incidence in years 1955-1999 was compared to that in 2000-2013.
RESULTS: Preoperatively, calcium and parathyroid hormone concentrations were higher in PC compared to APA and PA (1.76, 1.56 and 1.44 mmol/l, p < .001; and 989, 355 and 160 μmol/l, p < .001, respectively). Calcium was ≤1.77 mmol/l for all PAs. Hospitalization (44% vs. 22% and 3%, respectively, p = .01), renal (50% vs. 48% vs. 22%, respectively, p = .01) and bone (47% vs. 15% vs. 38%, respectively p = .002) manifestations were more common. PC and APA tumors were larger than PA (p < .001). Histopathological characteristics of PC compared to PA are increased mitotic activity (p= .001), chief cells (p = .003), diffuse growth pattern (p < .001), higher Ki67 (p< .001) and negative parafibromin (p < .001). One PC (1/18) and one APA (1/16) patient had a CDC73 mutation. After 6.7 (2-13.9) years of follow-up, 9.4% of PC had residual, 21% recurrent disease and 12.5% died of disease. Overall mortality did not differ between subgroups (p = .094). Recurrent PC was characterized by vascular invasion, lymph node metastases, high mitotic activity, necrosis and negative parafibromin. Incidence increased from 1.42 (range 0.52-2.14) to 7.14 (range 3.42-10.38)/10.000.000/years; (p < .001).
CONCLUSIONS: PC associates with severe primary hyperparathyroidism and must be suspected if calcium ≥1.77 mmol/l. The prevalence of CDC73 germline mutations in PC and APA in Finland is 6%. PC has distinct histopathological characteristics and its incidence has increased over the past decades.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28362521     DOI: 10.1080/0284186X.2017.1306103

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  26 in total

Review 1.  Immunohistochemistry in Diagnostic Parathyroid Pathology.

Authors:  Lori A Erickson; Ozgur Mete
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Epidemiology and prognosis of parathyroid carcinoma: real-world data using nationwide cohort.

Authors:  Sung Hye Kong; Jung Hee Kim; Man Young Park; Sang Wan Kim; Chan Soo Shin
Journal:  J Cancer Res Clin Oncol       Date:  2021-03-18       Impact factor: 4.553

Review 3.  Overview of the 2022 WHO Classification of Parathyroid Tumors.

Authors:  Lori A Erickson; Ozgur Mete; C Christofer Juhlin; Aurel Perren; Anthony J Gill
Journal:  Endocr Pathol       Date:  2022-02-17       Impact factor: 3.943

4.  Large Parathyroid Tumor 8 Years after Thyroid Surgery: A Case Report.

Authors:  Madara Ratniece; Elina Tauvena; Sergejs Pavlovics; Rita Niciporuka; Mara Liepa; Peteris Prieditis; Arturs Ozolins; Janis Gardovskis; Maija Radzina; Zenons Narbuts
Journal:  Case Rep Oncol       Date:  2022-05-16

5.  Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016.

Authors:  B Sun; B Guo; B Wu; J Kang; X Deng; Z Zhang; Y Fan
Journal:  Osteoporos Int       Date:  2017-12-03       Impact factor: 4.507

6.  Large deletion at the CDC73 gene locus and search for predictive markers of the presence of a CDC73 genetic lesion.

Authors:  Lucia Anna Muscarella; Daniela Turchetti; Andrea Fontana; Filomena Baorda; Orazio Palumbo; Annamaria la Torre; Danilo de Martino; Renato Franco; Nunzia Simona Losito; Andrea Repaci; Uberto Pagotto; Luigia Cinque; Massimiliano Copetti; Maria Grazia Chiofalo; Luciano Pezzullo; Paolo Graziano; Alfredo Scillitani; Vito Guarnieri
Journal:  Oncotarget       Date:  2018-04-17

7.  BROWN TUMORS SECONDARY TO PARATHYROID CARCINOMA MASQUERADING AS SKELETAL METASTASES ON 18F-FDG PET/CT: A CASE REPORT.

Authors:  Yumiko Tsushima; Simeng Sun; Michael A Via
Journal:  AACE Clin Case Rep       Date:  2019-03-13

8.  Parathyroid Carcinoma: A Single-Institution Experience with an Emphasis on Histopathological Features.

Authors:  Akash Pramod Sali; Priyal Motghare; Munita Bal; Neha Mittal; Swapnil Rane; Shubhada Kane; Asawari Patil
Journal:  Head Neck Pathol       Date:  2020-11-05

9.  Surgical Disparities of Parathyroid Carcinoma: Long-Term Outcomes and Deep Excavation Based on a Large Database.

Authors:  Ling Zhou; Yihui Huang; Wen Zeng; Sichao Chen; Wei Zhou; Min Wang; Wei Wei; Chao Zhang; Jianglong Huang; Zeming Liu; Liang Guo
Journal:  J Oncol       Date:  2021-05-27       Impact factor: 4.375

10.  Rare Somatic MEN1 Gene Pathogenic Variant in a Patient Affected by Atypical Parathyroid Adenoma.

Authors:  Luigia Cinque; Flavia Pugliese; Celeste Clemente; Stefano Castellana; Maria Pia Leone; Danilo de Martino; Teresa Balsamo; Claudia Battista; Tommaso Biagini; Paolo Graziano; Marco Castori; Alfredo Scillitani; Vito Guarnieri
Journal:  Int J Endocrinol       Date:  2020-04-27       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.